Abstract
During a phase 3 study evaluating the combination of sofosbuvir-velpatasvir for 12 weeks in patients with genotype 1, 2, 4, 5, and 6 hepatitis C virus (HCV) infection, we enrolled a patient who was subsequently found to be infected with genotype 7 HCV. This patient tolerated the study regimen well and achieved sustained virological response 12 weeks after treatment (SVR12). (Hepatology 2016;64:983-985).
© 2016 by the American Association for the Study of Liver Diseases.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antiviral Agents / therapeutic use*
-
Carbamates / therapeutic use*
-
Drug Combinations
-
Genotype
-
Hepacivirus / genetics*
-
Hepatitis C / drug therapy*
-
Hepatitis C / virology
-
Heterocyclic Compounds, 4 or More Rings / therapeutic use*
-
Humans
-
Male
-
Sofosbuvir / therapeutic use*
Substances
-
Antiviral Agents
-
Carbamates
-
Drug Combinations
-
Heterocyclic Compounds, 4 or More Rings
-
sofosbuvir-velpatasvir drug combination
-
Sofosbuvir